Maximus, Inc. (NYSE:MMS – Get Free Report) insider Michelle Link sold 3,208 shares of the firm’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $54.23, for a total transaction of $173,969.84. Following the sale, the insider owned 13,881 shares in the company, valued at approximately $752,766.63. The trade was a 18.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Maximus Stock Down 1.5%
MMS traded down $0.81 during trading on Friday, hitting $52.72. The company had a trading volume of 609,756 shares, compared to its average volume of 710,019. The company has a market capitalization of $2.76 billion, a PE ratio of 7.79 and a beta of 0.59. The company has a quick ratio of 2.42, a current ratio of 2.42 and a debt-to-equity ratio of 0.90. Maximus, Inc. has a one year low of $51.04 and a one year high of $100.00. The firm’s 50-day moving average price is $57.45 and its 200 day moving average price is $60.34.
Maximus (NYSE:MMS – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The health services provider reported $2.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.21 by $0.01. The firm had revenue of $1.28 billion for the quarter, compared to the consensus estimate of $1.33 billion. Maximus had a return on equity of 24.91% and a net margin of 7.07%.The company’s revenue for the quarter was down 5.1% on a year-over-year basis. During the same quarter last year, the business posted $2.16 EPS. Maximus has set its FY 2026 guidance at 7.900-8.200 EPS. As a group, equities analysts expect that Maximus, Inc. will post 8.03 earnings per share for the current year.
Maximus Announces Dividend
Wall Street Analysts Forecast Growth
A number of brokerages have recently commented on MMS. Zacks Research lowered shares of Maximus from a “hold” rating to a “strong sell” rating in a research report on Tuesday, August 11th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Maximus in a research report on Monday, August 17th. Finally, Wall Street Zen lowered shares of Maximus from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Reduce”.
Check Out Our Latest Research Report on MMS
Hedge Funds Weigh In On Maximus
A number of institutional investors have recently added to or reduced their stakes in the company. Empowered Funds LLC acquired a new stake in Maximus in the 2nd quarter valued at about $504,000. Hsbc Holdings PLC acquired a new position in shares of Maximus during the 2nd quarter worth approximately $956,000. Reinhart Partners LLC. increased its holdings in shares of Maximus by 131.8% in the second quarter. Reinhart Partners LLC. now owns 1,982,415 shares of the health services provider’s stock valued at $106,575,000 after purchasing an additional 1,127,346 shares during the last quarter. Assenagon Asset Management S.A. acquired a new position in Maximus in the 2nd quarter valued at about $1,719,000. Finally, Corient Private Wealth LP acquired a new position in shares of Maximus in the second quarter valued at approximately $1,984,000. 97.21% of the stock is currently owned by institutional investors and hedge funds.
Maximus Company Profile
Maximus, Inc (NYSE:MMS) is a provider of government services and technology-enabled solutions. The company partners with federal, state, provincial and local governments to administer public programs, improve service delivery and support interactions between governments and the people they serve.
Its business activities include health and human services administration, employment and workforce services, child support and eligibility services, customer contact centers, program management, consulting and digital transformation.
Read More
- Five stocks we like better than Maximus
- AST SpaceMobile’s BlueBird Progress Comes With Several Risks Still Unresolved
- Time to Nibble on MCD Stock After it Enters Oversold Territory?
- McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal Upside
- Corning and AT&T’s $3 Billion Fiber Deal Reveals Where AI Spending Goes Next
Receive News & Ratings for Maximus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus and related companies with MarketBeat.com's FREE daily email newsletter.
